Anti-Vascular Endothelial Growth Factor Therapeutics Market Report 2025

The anti-vascular endothelial growth factor therapeutics market size has grown marginally in recent years. It will grow from $12.2 billion in 2024 to $12.31 billion in 2025 at a compound annual growth rate (CAGR) of 1%. The growth in the historic period can be attributed to rise in age-related macular degeneration, increased incidence of diabetic retinopathy, advancements in retinal disease diagnosis, clinical success and efficacy, shift to outpatient treatment.

The anti-vascular endothelial growth factor therapeutics market size is expected to see steady growth in the next few years. It will grow to $13.49 billion in 2029 at a compound annual growth rate (CAGR) of 2.3%. The growth in the forecast period can be attributed to aging population and ocular diseases, expanding applications in retinal disorders, development of next-generation therapeutics, increasing emphasis on early intervention, global health initiatives and access to treatment. Major trends in the forecast period include increasing utilization in cancer treatment, focus on combination therapies in ophthalmology, exploration of biosimilar versions, research on resistance mechanisms, integration with imaging technologies.

The rise in the incidence of ophthalmic diseases is anticipated to drive the expansion of the anti-vascular endothelial growth factor therapeutics market. Ophthalmic disease prevalence signifies the occurrence of specific eye conditions or disorders within a given population. Anti-vascular endothelial growth factor (VEGF) therapeutics play a pivotal role in combating prevalent eye ailments such as wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. As of October 2022, the World Health Organization reported global vision impairment affecting approximately 2.2 billion people, with specific conditions impacting 1 billion individuals, including 8 million with age-related macular degeneration and approximately 3.9 million experiencing diabetic retinopathy. This prevalence underscores the driving force behind the growth of the anti-vascular endothelial growth factor therapeutics market.

Increasing investment in healthcare infrastructure is anticipated to drive the growth of the anti-vascular endothelial growth factor (VEGF) therapeutics market in the future. This expenditure encompasses the financial resources allocated to developing, maintaining, and enhancing healthcare facilities and assets, including hospitals, clinics, medical equipment, and information systems. Such investments play a vital role in the anti-VEGF therapeutics market by improving treatment accessibility, facilitating the adoption of new technologies, raising awareness and promoting early detection, and encouraging public-private partnerships in research and development. For example, in May 2024, the Office for National Statistics, a UK-based government agency, reported that total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared to a mere 0.9% growth in 2022. Thus, the rising investment in healthcare infrastructure is propelling the growth of the anti-VEGF therapeutics market.

Advancements in therapeutic approaches represent a prominent trend driving growth within the anti-vascular endothelial growth factor therapeutics market. Companies active in this domain are embracing cutting-edge therapeutic methodologies to fortify their market presence. For instance, in May 2022, Ashvattha Therapeutics Inc., a US-based biopharmaceutical firm, disclosed phase 1 safety data for healthy subjects concerning their subcutaneous anti-VEGF wet AMD and DME candidates, namely D-4517.2 therapy. D-4517.2 is an innovative therapy designed to target unaddressed needs in DME conditions. Notably, this therapy is designed for self-administration through an autoinjector, allowing patients the convenience of self-administering the medication once monthly from the comfort of their homes.

Major players within the anti-vascular endothelial growth factor therapeutics sphere are strategically aligning through partnerships to propel the development and commercialization of VEGF inhibitors, thereby optimizing market gains. Such collaborations play a pivotal role in steering research and development, accessing novel technologies and candidates, expanding market penetration, and facilitating the commercial launch of VEGF inhibitors. For example, in June 2022, Biogen Inc., a US-based biotech enterprise, in collaboration with Samsung Bioepis, a South Korea-based biopharmaceutical company, introduced BYOOVIZ (ranibizumab-nuna) in the United States. BYOOVIZ stands as the premier FDA-endorsed ophthalmology biosimilar, specifically tailored for treating neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion, and myopic choroidal neovascularization. Functioning as a vascular endothelial growth factor (VEGF) inhibitor, BYOOVIZ marks the inaugural biosimilar launch in the U.S. within the Biogen and Samsung Bioepis partnership. Under this collaboration, Samsung Bioepis is accountable for development, regulatory processes, and product manufacture, while Biogen shoulders the responsibility for commercialization.

In August 2022, Coherus BioSciences Inc., a US-based commercial-stage biopharmaceutical company, acquired the commercialization rights to FYB203 from Klinge Biopharma GmbH for an undisclosed amount. This acquisition significantly enhances Coherus's portfolio of ophthalmology products, particularly within the anti-vascular endothelial growth factor (anti-VEGF) segment. Klinge Biopharma GmbH, based in Germany, specializes in pharmaceutical manufacturing, and this deal allows Coherus to strengthen its position in the growing market for therapies targeting conditions such as age-related macular degeneration and diabetic retinopathy, which are treated using anti-VEGF medications.

Major companies operating in the anti-vascular endothelial growth factor therapeutics market include F. Hoffmann-La Roche AG, Biogen Inc., Pfizer Inc., Coherus BioSciences Inc., Eli Lilly and Company, Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc, Allergan Inc., Novartis AG, kyowa Kirin Co. Ltd., Amgen Inc., AstraZeneca plc, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc.

North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2024. Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anti-vascular endothelial growth factor therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Anti-vascular endothelial growth factor (VEGF) therapeutics constitute a class of medications designed to impede the growth of blood vessels, particularly prevalent in the treatment of ophthalmic conditions. These drugs function by inhibiting vascular endothelial growth factors and find widespread application in the therapeutic intervention of various tumors and age-related macular degeneration.

The primary products within the category of anti-vascular endothelial growth factor therapeutics include Eylea, Lucentis, and Beovu. Eylea is a medication specifically indicated for the treatment of certain eye conditions, such as macular degeneration and diabetic retinopathy. Serving as an anti-VEGF therapeutic agent, Eylea effectively hinders the abnormal growth of blood vessels in the eye, particularly associated with retinal diseases. The utilization of anti-vascular endothelial growth factor therapeutics extends to the treatment of macular edema, diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration. These therapeutics are commonly employed by hospitals, clinics, oncology centers, and other healthcare facilities in addressing a range of ophthalmic disorders.

The anti-vascular endothelial growth factor therapeutics market research report is one of a series of new reports that provides anti-vascular endothelial growth factor therapeutics market statistics, including anti-vascular endothelial growth factor therapeutics industry global market size, regional shares, competitors with a anti-vascular endothelial growth factor therapeutics market share, detailed anti-vascular endothelial growth factor therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the anti-vascular endothelial growth factor therapeutics industry. This anti-vascular endothelial growth factor therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-vascular endothelial growth factor therapeutics market consists of revenues earned by entities by providing lapatinib (tykerb), sorafenib (nexavar), sunitinib (sutent), axitinib, and pazopanib. The market value includes the value of related goods sold by the service provider or included within the service offering. The anti-vascular endothelial growth factor therapeutics market also includes sales of drugs, injectables, and therapy-related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.